Effect of Magnesium Supplement in Early Pregnancy After ICSI
Magnesium Supplement in Early Pregnancy After ICSI
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
a fall of magnesium levels at 2-3 weeks of gestation. This drop of magnesium concentration is larger following IVF as compared to spontaneous pregnancies.
so magnesium supplement start after biochemical diagnosis of pregnancy and throughout the 1st trimester
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Abbassya
-
Cairo, Abbassya, Egypt, 02002
- Recruiting
- Ainshams University maternity hospital
-
Contact:
- ahmed m Abbas, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age 25_38 years
BMI 25_30
- females pregnant after ICSI after biochemical diagnosis of pregnancy
Exclusion Criteria:
females with poor ovarian reserve and poor responders
- abnormality in uterine cavity detected by hysteroscopic evaluation pre ICSI and not treated
- hydrosalpinx
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Magnesium supplement
90 female pregnant after ICSI after biochemical diagnosis of pregnancy will receive 500 mg magnesium supplement
|
After biochemical diagnosis of pregnancy each participant will receive magnesium plus 500 mg tablet once daily till the end of the 1st trimester
Other Names:
|
|
Placebo Comparator: placebo
90 female pregnant after ICSI after biochemical diagnosis of pregnancy will receive placebo oral tablet
|
After biochemical diagnosis of pregnancy each participant will receive placebo tablet once daily till the end of the 1st trimester
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
1st trimesteric abortion
Time Frame: 13 week of gestation
|
Either spontaneous or missed abortion
|
13 week of gestation
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ashams university
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.